News features

10/10/2016

It takes Tau to Tangle

AC Immune’s partner Genentech has published an editorial which summarizes the biology of Alzheimer’s disease (AD) and describes the importance of tau as a target in AD. Written in an accessible and informative way, the editorial also explains...

AC Immune’s partner Genentech has published an editorial which summarizes the biology of Alzheimer’s disease (AD) and describes the importance of tau as a target in AD. Written in an accessible and informative way, the editorial also explains why selecting the right type of antibody is key as was recently published in Cell Reports by Gai Ayalon et al.

In 2006, AC Immune closed an exclusive out-licensing agreement for its anti-Abeta antibody program with Genentech, under which Genentech develops crenezumab for the treatment of Alzheimer's disease.

In 2012, AC Immune entered into a second exclusive worldwide license agreement and research collaboration with Genentech for the research, development and commercialization of AC Immune’s anti-Tau antibodies.

It takes Tau to Tangle

AC Immune’s partner Genentech has published an editorial which summarizes the biology of Alzheimer’s disease (AD) and describes the...

AC Immune’s partner Genentech has published an editorial which summarizes the biology of Alzheimer’s disease (AD) and describes the importance of tau as a target in AD. Written in an accessible and informative way, the editorial also explains why selecting the right type of antibody is key as was recently published in Cell Reports by Gai Ayalon et al.

In 2006, AC Immune closed an exclusive out-licensing agreement for its anti-Abeta antibody program with Genentech, under which Genentech develops crenezumab for the treatment of Alzheimer's disease.

In 2012, AC Immune entered into a second exclusive worldwide license agreement and research collaboration with Genentech for the research, development and commercialization of AC Immune’s anti-Tau antibodies.